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Cell therapy has been on the rise in recent years. It consists in the treatment of therapeutic cells to be transferred 
to human patients, and is applied in multiple pathologies such as hemophilia or muscular dystrophies. Several 
cell treatment solutions are currently developed, including the use of transcription factors or genome editing 
technologies. These ex vivo technologies often require gene transfer to express the therapeutic protein in the 
treated cells. The genes are delivered mainly by transfection or viral transduction, causing regulatory limitations 
for clinical studies. 
 
A promising strategy is to avoid the use of nucleic acids by direct delivery of the therapeutic protein. This approach 
permits a transient treatment of the cells and the control of the intracellular dose of the protein. Lipids and cationic 
polymers offer efficient cargo delivery but present strong cell toxicity, inconsistent with human therapy. In the case 
of the genome editing revolution, the Cas9 system is often transferred in several plasmids, or delivered in protein 
with its RNA by electroporation. However, this method is afflicted by high cost, inconsistency and cell mortality. 
Moreover some cell lines are impervious to genome editing. 
 
We are presently developing protein-based shuttles, designed for protein delivery in mammalian cells, 
specifically for cell therapy. This shuttle permits an efficient delivery of protein cargos in multiple cell lines, and is 
able to aim different cell compartments. Our technology has been applied for the delivery of fluorescent proteins 
(GFP, mCherry), antibodies, a transcription factor, and also the Cas9 nuclease. Our technology has a low 
cytotoxicity and the naturally degradable shuttle offers a transient and controlled delivery. The absence of gene 
transfer makes it suitable with safety regulation. Feldan Shuttle is a high potential method which can be a strong 
contender for cell therapy applications, bringing transcription factors development and genome editing 
technologies to clinical studies. 
